The recently released fifth G-FINDER survey reports on 2011 global investment into research and development of new products for neglected diseases, and identifies trends and patterns across the five years of global G-FINDER data.
In 2011, reported funding for neglected disease R&D was $3.05 billion. Between 2007 and 2009, investment in neglected disease R&D increased steadily, but has been in gradual decline since the impact of the global financial crisis became evident. Despite this, annual year-on-year (YOY) funding for neglected disease R&D was still $443.7m higher in 2011 than in 2007 ($2,902m compared to $2,459m).
Both public and philanthropic funding have dropped away since the global financial crisis, but industry funding has increased dramatically over the survey period, predominantly due to increased investments from multinational pharmaceutical companies (MNCs).
- $3.05bn Investment into R&D for new neglected disease products in 2011
- $443.7m Increase in global investment in neglected disease R&D since 2007
- $193.6m Increase in multinational pharmaceutical company investment since 2008
Between 2007 and 2011, funding shifted away from the top tier diseases (HIV/AIDS, malaria and tuberculosis (TB)), which saw their share of global funding fall from 76.6% in 2007 to 69.4% in 2011, to the second tier diseases (dengue, diarrhoeal diseases, kinetoplastids, bacterial pneumonia & meningitis, helminth infections and salmonella infections), which increased their global share from 16.2% to 24.1%. The third tier diseases (trachoma, leprosy, Buruli ulcer and rheumatic fever) remained poorly-funded throughout, collectively receiving less than 1% of global funding each year.
Read the G-FINDER 2012 summary
Read the full G-FINDER 2012 report